Pharmacokinetics and pharmacodynamics of erythropoietin during therapy in an infant with renal failure.
We treated an infant with anemia and chronic renal failure with recombinant human erythropoietin (300 to 750 U/kg subcutaneously per week) and iron (6 mg/kg enterally) from 1 to 4 months of age. A suboptimal pharmacodynamic response was seen at the lower dose. This may have been due to developmental erythropoietin pharmacokinetic differences, that is, relatively greater neonatal plasma clearance and steady-state volume of distribution compared with those in adults.
Kling
P J
PJ
Department of Pediatrics, College of Medicine, University of Iowa, Iowa City.
Widness
J A
JA
Guillery
E N
EN
Veng-Pedersen
P
P
Peters
C
C
DeAlarcon
P A
PA
D000740:Anemia / Q000628:therapy; D004921:Erythropoietin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism*; D008297:Male
D004921:Erythropoietin